Investors - Carvolix

Millions of People around the World… Are Waiting for Solutions

Biotech Finance Webinar – January 8, 2026
Democratizing healthcare, everywhere and for everyone: Carvolix’s vision

Carvolix highlights the clinical and regulatory advances of its innovative Artus medical device in an exclusive interview on Boursorama

Presentation at LSI Europe ’24
Emerging MedTech Summit 2024 (Lisbon)
Sébastien Ladet, CEO

Interview with Michel Therin, Chairman of the Board of Directors and Sébastien Ladet, CEO, in the “Actu Bourse” issue on Boursorama

Interview with Michel Therin, Chairman of the Board of Directors and Sébastien Ladet, CEO, in the “Actu Bourse” issue on Boursorama

Watch the video

Interview with Michel Thérin and Sébastien Ladet on Bourse Direct

Financial releases Financial documentation Regulated Information Events Shareholders’ corner

Let the Numbers Speak

Heart valve replacement

17% of eligible patients receive TAVI

4% of patients with severe mitral regurgitation undergo surgery

Stroke treatment

Less than 5% of ischemic stroke patients have access to mechanical thrombectomy

2nd cause of death

1st cause of acquired handicap

A High-Growth Market…

The market is growing thanks to a high prevalence of mitral regurgitation, the world’s ageing population and the appearance of less invasive solutions.

…with High Potential
Only a very small number of patients are currently being treated for these two conditions.

Undeniable Savings for the Health System

Less invasive and faster to implant, allowing patients to recover quicker and, for some, avoid further major surgery, Affluent’s solutions will have a direct impact on health costs for mitral insufficiency and urinary incontinence.

Simplified Use

Easier and quicker to place, Affluent solutions will provide increased reassurance to surgical teams. They will also create less stress since the risk of complications will be lower, and patient recovery faster.

Greater Peace of Mind for Millions of Patients

A single objective for this team of doctors and engineers: improve patients’ comfort and daily life with new and ambitious solutions, adapted above all to their anatomy and physiology. Affluent solutions are a demonstration of when research serves the promise of a new life.

Carvolix’s ambition is to become, thanks to its major innovations, a future global player in medtech specializing in urology and cardiology”.

Sébastien Ladet, Ph.D., Chief Executive Officer

Financial releases

02/02/2026: Carvolix is born and funded

19/12/2025: Carvolix announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix

30/10/2025: Promising results for the Epygon biomimetic mitral valve presented at the TCT cardiology congress in the United States

30/09/2025: H1 2025 Results

29/09/2025: Carvolix announces that the clinical results of the Artus were presented at the international conferences of the UAA and the ICS

24/06/2025: Carvolix extends the horizon of its cash position to end-2025 with support from its key shareholders

15/05/2025: Carvolix announces promising performance results for its Artus artificial urinary sphincter and receives approval to initiate pivotal phase of its clinical trial

24/04/2025: 2024 FULL YEAR RESULTS – Carvolix reached major new milestones in executing its clinical roadmap

15/04/2025: Carvolix Announces Progress Toward European Clinical Study of Artificial Sphincter Artus

11/03/2025: Carvolix announces several key appointments for Medical and Clinical affairs

25/02/2025: Carvolix appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

30/01/2025: Carvolix announces 10th successful human implantation of its Artus urinary sphincter, marking completion of the pilot phase

08/10/2024: Carvolix Announces Participation in Upcoming Scientific Events

26/09/2024: H1 2024 results

12/09/2024: Carvolix takes stock of its recent operational advances

22/08/2024: Carvolix to attend German Fall Conference in Frankfurt in September 2024

15/07/2024: Carvolix announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of a category of beneficiaries

12/07/2024: Carvolix signs agreements for mitral valve technologies with EUR 15M upfront payment

18/06/2024: Carvolix achieves the clinical objective of the Dry pilot study in the first two patients with the Artus artificial urinary sphincter

25/04/2024: 2023 financial results and update on clinical activities under development

04/04/2024: Carvolix announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group

28/03/2024: Carvolix announces coverage initiation of its stock by TP ICAP Midcap

12/03/2024: Carvolix announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence

29/02/2024: Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve

29/01/2024: Carvolix closes €3.5 million bridge via capital increase from key shareholders

15/01/2024: Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review

2023/12/06: Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence

2023/11/27: Carvolix announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribastifs

2023/09/28: H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024

2023/09/13: Carvolix announces positive clinical results and further insights to enhance its strategy on Structural Heart activities

2023/07/17: Carvolix strengthens management team to advance its development

2023/04/26: Publication of the Universal Registration Document (URD) 20222023/04/17: Very positive results one month after Epygon mitral heart valve implantation in a first patient

2023/04/04: Carvolix: significant strengthening of Mr. Laurent Saglio’s stake, through his company LCEA, to 10.25% of the capital.

2023/03/29: 2022 full year results and update on clinical activities under development.

2023/03/09: Carvolix announces initial success of first clinical implantation of its Epygon mitral heart valve via minimally invasive route

2023/03/06: Carvolix announces the major success of its capital increase with preferential subscription rights for about €13.7 million

2023/02/09: Carvolix announces the launch of a capital increase of around €13 million with preferential subscription rights maintained by shareholders

2023/01/16: Carvolix strengthens its management team to support industrial and commercial deployment

2022/12/07: Carvolix announces the appointment of Michel Therin as Chairman of the Board of Directors2022/10/24: Pivotal study progresses to 24 patients successfully implanted with Kalios™, an adjustable mitral ring that avoids complex re-interventions2022/09/28: Financial results for H1 2022 and significant progresses in 20222022/08/22: Carvolix is evolving its governance to accelerate its development2022/07/26: Carvolix reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios™, adjustable mitral ring, in the treatment of mitral regurgitation2022/07/11: Carvolix appoints Dr. Christophe Giot Vice President Clinical Affairs2022/04/29: Publication of the Universal Registration Document (URD) 20212022/04/14: Coverage initiation by Kepler Cheuvreux2022/03/29: 2021 full-year results and update on clinical programs2022/01/24: Financial communication calendar2022/01/19: Appointment of a new independent board member to the Carvolix Board of Directors
2021/09/22: Financial results for the first half of 2021 and main clinical update

2021/09/16: Successful first post-operative adjustment of KaliosTM mitral ring

2021/07/13: Financial communication schedule for the second half of 2021

2021/06/09: Carvolix announces the success of its initial public offering on the Euronext Paris regulated market

2021/05/27: IPO launch on Euronext Paris

2021/04/13: Approval of the Registration Document

Financial documentation

02/02/2026: Results of the votes of the Combined Shareholders’ General Meeting of January 30, 2026
20/11/2024: Half-year financial report
01/07/2024: 2023 Universal Registration Document
2023/10/13: Half-year financial report2023/10/13: 2022 Universal Registration Document
2022/09/28: Half-year financial report2022/04/29: 2021 Universal Registration Document
2021/09/22: Half-year financial report at 30 June 2021

2021/05/27: Investor presentation

2021/05/27: Registration Document

2021/05/27: IOM

Events

19 -21
November 2023

PCR London Valves – Conference, London

1
November 2023

LSX Inv€$tival – Conference, London

23 – 26
October 2023

TCT (Transcatheter Cardiovascular Therapeutics) – Conference, San Francisco – USA

Shareholders’ corner

INFORMATION ON THE SHARE

IPO date: June 14, 2021
Label: CARVOLIX
ISIN Code: FR0013333077
Mnemonic: CVX
ICB classification: 4535 – Medical Equipment – 20102010 – Medical Equipment
Listing market: Euronext Paris

Carvolix on the stock exchange
Capital breakdown as of January 30th, 2026

Analyst coverage

Clément BASSAT
clement.bassat@bnpparibas.com

Thibaut VOGLIMACCI – STEPHANOPOLI
tvoglimacci@invest-securities.com

Read Kepler Cheuvreux’s latest note ›

Nicolas PAUILLAC
npauillac@keplercheuvreux.com

Corentin MARTY
corentin.marty@tpicap.com

Annual general meeting

How to participate in the Annual General Meeting of Shareholders?

1. You wish to attend the Annual General Meeting

If your shares are registered, you will receive a summons file from CACEIS, the securities department of Carvolix. All you have to do is go to the Annual General Meeting of Shareholders, with an identity document. If your securities are bearer shares, you must ask your bank to immobilize your securities and go to the Annual General Meeting with a certificate of immobilization, which will allow you to take part in the vote of the resolutions.

2. You wish to vote by mail

You do not wish, or you cannot attend the Annual General Meeting. Three possible options for voting:

  • Vote by mail by expressing your opinion on each of the proposed resolutions,
  • Give power to the President,
  • Or have you represented by another person.

    Carvolix Securities Service: the securities department and the financial service of the shares of Carvolix are provided by:

    CACEIS
    ISSY-LES-MOULINEAUX
    14 rue Rouget de Lisle
    92862 Issy-les-Moulineaux Cedex 09
    +33 1 57 78 00 00

    Investor relations contacts

    Sébastien Ladet
    Chief Executive Officer
    investor@carvolix.eu

    Ghislaine Gasparetto
    Investor Relations
    carvolix@seitosei-actifin.com

    Subscribe to our news